Early study of Covid-19 vaccine developed in China sees mixed results
A Covid-19 vaccine candidate being developed by a Chinese drug maker appeared to induce an immune response in some subjects, but also showed some concerning although not unexpected results.
Data on the vaccine, made by CanSino Biologics, were published Friday in the Lancet, the first time Phase 1 trial data from any Covid-19 vaccine have been published in a scientific journal. The results are likely to be closely examined, particularly in Canada, which recently announced it would test the vaccine and produce it there if results of the early studies were positive.
Read Original Article: Early study of Covid-19 vaccine developed in China sees mixed results »
